Haematological cancer: Optimizing the treatment of multiple myeloma. Morgan GJ et al. Nat Rev Clin Oncol. 2014 Oct 28. doi: 10.1038/nrclinonc.2014.185. [Epub ahead of print]. The Role of Bendamustine in the Management of Plasma Cell Myeloma. Gertz MA. Leuk Lymphoma. 2014 Oct 27:1-5. [Epub ahead of print]. Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant…
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Blimark C et al. Haematologica. 2014 Oct 24. pii: haematol.2014.107714. [Epub ahead of print]. Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy. Li J et al. Cell Biochem Biophys. 2014…
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Tuchman SA et al. J Clin Apher. 2014 Oct 8. doi: 10.1002/jca.21360. [Epub ahead of print]. Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in chinese patients. Lin M et al. Adv Ther. 2014…
This guideline outlines recommendations for the diagnosis and investigation of patients with suspected AL amyloidosis.
These guidelines outline recommendations for the management of patients with AL amyloidosis, including treatment, monitoring and how to measure response.
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit candidate vaccine in adult autologous hematopoietic stem-cell transplant recipients. Stadtmauer EA et al. Blood. 2014 Sep 18. pii: blood-2014-04-573048. [Epub ahead of print]. Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of…
Harnessing the immune system for cancer therapy. Smith EL et al. Curr Opin Oncol. 2014 Sep 23. [Epub ahead of print]. CCN1: a sticky issue in myeloma. Roodman GD. Blood. 2014 Sep 25;124(13):2006-8. doi: 10.1182/blood-2014-08-592303. Appraising Myc involvement in high risk myeloma. Kastritis E et al. Leuk Lymphoma. 2014 Sep 26:1-5. [Epub ahead of print].…
Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Engels EA et al. Bone Marrow Transplant. 2014 Sep 29. doi: 10.1038/bmt.2014.213. [Epub ahead of print]. Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study. Kashyap R et al. Asia Pac J Clin Oncol. 2014 Sep 22.…
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. Benboubker L et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Moreau P et al. Br J Haematol. 2014 Sep 19. doi: 10.1111/bjh.13128. [Epub ahead of print]. Bortezomib, thalidomide and…
Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Higo H et al. Intern Med. 2014;53(16):1809-12. Epub 2014 Aug 15. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Kourelis TV et al. Am J Hematol. 2014 Aug 11. doi: 10.1002/ajh.23827. [Epub ahead of print]. Immunophenotypic analysis of…